Breast cancer

The impact of depression and its treatment

Ephi Betan, Hannah Larsen, Wendy Somerset, Steven C. Stout, Angela Bowling, Dominique Musselman

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

A series of difficult life adjustments is initiated the moment a woman receives her diagnosis of breast cancer, arguably one of the most challenging of life stressors. (Table presented) Elevated rates of major depression are observed in women with breast cancer. This disorder of the CNS interferes with a woman's capacity for problem solving and self-care, impairs her compliance with the antineoplastic regimen, adversely affects her quality of life, and is associated with diminished survival. Depressive symptoms in cancer patients are thought to be induced by pathophysiologic mechanisms such as elevations of proinflammatory cytokines and HPA axis hyperactivity. The acute perturbation of gonadal steroid production by chemotherapy can be conceptualized as being analogous to the perimenopause, the maturational phase in which women are especially susceptible to major depression. Antidepressant treatment reduces the incidence of hot flashes and has been shown to improve depressive symptoms in women with breast cancer suffering from comorbid major depression. With documented effectiveness in amelioration of depressive symptoms (and improvement in quality of life) of breast cancer survivors, group psychotherapy also provides education, techniques to reduce some of the adverse effects of chemotherapy, and improvement in pain control. Further understanding of the molecular pathways by which antineoplastic therapeutic regimens induce depressive symptoms and related symptoms of fatigue and cognition dysfunction can only catalyze the development of neuroprotective strategies to prevent mood syndromes in women with breast cancer. Whether group psychotherapy alone and/or in combination with antidepressant treatment enhances a woman's compliance with oncologic treatment, and thereby improves her survival, will undoubtedly be elucidated in the next decade [85].

Original languageEnglish
Title of host publicationBreast Cancer and Molecular Medicine
PublisherSpringer Berlin Heidelberg
Pages945-975
Number of pages31
ISBN (Print)3540282653, 9783540282655
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

Depression
Breast Neoplasms
Group Psychotherapy
Antineoplastic Agents
Therapeutics
Antidepressive Agents
Perimenopause
Quality of Life
Hot Flashes
Social Adjustment
Drug Therapy
Survival
Self Care
Cognition
Fatigue
Survivors
Steroids
Cytokines
Education
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Betan, E., Larsen, H., Somerset, W., Stout, S. C., Bowling, A., & Musselman, D. (2006). Breast cancer: The impact of depression and its treatment. In Breast Cancer and Molecular Medicine (pp. 945-975). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_44

Breast cancer : The impact of depression and its treatment. / Betan, Ephi; Larsen, Hannah; Somerset, Wendy; Stout, Steven C.; Bowling, Angela; Musselman, Dominique.

Breast Cancer and Molecular Medicine. Springer Berlin Heidelberg, 2006. p. 945-975.

Research output: Chapter in Book/Report/Conference proceedingChapter

Betan, E, Larsen, H, Somerset, W, Stout, SC, Bowling, A & Musselman, D 2006, Breast cancer: The impact of depression and its treatment. in Breast Cancer and Molecular Medicine. Springer Berlin Heidelberg, pp. 945-975. https://doi.org/10.1007/978-3-540-28266-2_44
Betan E, Larsen H, Somerset W, Stout SC, Bowling A, Musselman D. Breast cancer: The impact of depression and its treatment. In Breast Cancer and Molecular Medicine. Springer Berlin Heidelberg. 2006. p. 945-975 https://doi.org/10.1007/978-3-540-28266-2_44
Betan, Ephi ; Larsen, Hannah ; Somerset, Wendy ; Stout, Steven C. ; Bowling, Angela ; Musselman, Dominique. / Breast cancer : The impact of depression and its treatment. Breast Cancer and Molecular Medicine. Springer Berlin Heidelberg, 2006. pp. 945-975
@inbook{27003641fcd842318bb5af08c294807a,
title = "Breast cancer: The impact of depression and its treatment",
abstract = "A series of difficult life adjustments is initiated the moment a woman receives her diagnosis of breast cancer, arguably one of the most challenging of life stressors. (Table presented) Elevated rates of major depression are observed in women with breast cancer. This disorder of the CNS interferes with a woman's capacity for problem solving and self-care, impairs her compliance with the antineoplastic regimen, adversely affects her quality of life, and is associated with diminished survival. Depressive symptoms in cancer patients are thought to be induced by pathophysiologic mechanisms such as elevations of proinflammatory cytokines and HPA axis hyperactivity. The acute perturbation of gonadal steroid production by chemotherapy can be conceptualized as being analogous to the perimenopause, the maturational phase in which women are especially susceptible to major depression. Antidepressant treatment reduces the incidence of hot flashes and has been shown to improve depressive symptoms in women with breast cancer suffering from comorbid major depression. With documented effectiveness in amelioration of depressive symptoms (and improvement in quality of life) of breast cancer survivors, group psychotherapy also provides education, techniques to reduce some of the adverse effects of chemotherapy, and improvement in pain control. Further understanding of the molecular pathways by which antineoplastic therapeutic regimens induce depressive symptoms and related symptoms of fatigue and cognition dysfunction can only catalyze the development of neuroprotective strategies to prevent mood syndromes in women with breast cancer. Whether group psychotherapy alone and/or in combination with antidepressant treatment enhances a woman's compliance with oncologic treatment, and thereby improves her survival, will undoubtedly be elucidated in the next decade [85].",
author = "Ephi Betan and Hannah Larsen and Wendy Somerset and Stout, {Steven C.} and Angela Bowling and Dominique Musselman",
year = "2006",
month = "12",
day = "1",
doi = "10.1007/978-3-540-28266-2_44",
language = "English",
isbn = "3540282653",
pages = "945--975",
booktitle = "Breast Cancer and Molecular Medicine",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Breast cancer

T2 - The impact of depression and its treatment

AU - Betan, Ephi

AU - Larsen, Hannah

AU - Somerset, Wendy

AU - Stout, Steven C.

AU - Bowling, Angela

AU - Musselman, Dominique

PY - 2006/12/1

Y1 - 2006/12/1

N2 - A series of difficult life adjustments is initiated the moment a woman receives her diagnosis of breast cancer, arguably one of the most challenging of life stressors. (Table presented) Elevated rates of major depression are observed in women with breast cancer. This disorder of the CNS interferes with a woman's capacity for problem solving and self-care, impairs her compliance with the antineoplastic regimen, adversely affects her quality of life, and is associated with diminished survival. Depressive symptoms in cancer patients are thought to be induced by pathophysiologic mechanisms such as elevations of proinflammatory cytokines and HPA axis hyperactivity. The acute perturbation of gonadal steroid production by chemotherapy can be conceptualized as being analogous to the perimenopause, the maturational phase in which women are especially susceptible to major depression. Antidepressant treatment reduces the incidence of hot flashes and has been shown to improve depressive symptoms in women with breast cancer suffering from comorbid major depression. With documented effectiveness in amelioration of depressive symptoms (and improvement in quality of life) of breast cancer survivors, group psychotherapy also provides education, techniques to reduce some of the adverse effects of chemotherapy, and improvement in pain control. Further understanding of the molecular pathways by which antineoplastic therapeutic regimens induce depressive symptoms and related symptoms of fatigue and cognition dysfunction can only catalyze the development of neuroprotective strategies to prevent mood syndromes in women with breast cancer. Whether group psychotherapy alone and/or in combination with antidepressant treatment enhances a woman's compliance with oncologic treatment, and thereby improves her survival, will undoubtedly be elucidated in the next decade [85].

AB - A series of difficult life adjustments is initiated the moment a woman receives her diagnosis of breast cancer, arguably one of the most challenging of life stressors. (Table presented) Elevated rates of major depression are observed in women with breast cancer. This disorder of the CNS interferes with a woman's capacity for problem solving and self-care, impairs her compliance with the antineoplastic regimen, adversely affects her quality of life, and is associated with diminished survival. Depressive symptoms in cancer patients are thought to be induced by pathophysiologic mechanisms such as elevations of proinflammatory cytokines and HPA axis hyperactivity. The acute perturbation of gonadal steroid production by chemotherapy can be conceptualized as being analogous to the perimenopause, the maturational phase in which women are especially susceptible to major depression. Antidepressant treatment reduces the incidence of hot flashes and has been shown to improve depressive symptoms in women with breast cancer suffering from comorbid major depression. With documented effectiveness in amelioration of depressive symptoms (and improvement in quality of life) of breast cancer survivors, group psychotherapy also provides education, techniques to reduce some of the adverse effects of chemotherapy, and improvement in pain control. Further understanding of the molecular pathways by which antineoplastic therapeutic regimens induce depressive symptoms and related symptoms of fatigue and cognition dysfunction can only catalyze the development of neuroprotective strategies to prevent mood syndromes in women with breast cancer. Whether group psychotherapy alone and/or in combination with antidepressant treatment enhances a woman's compliance with oncologic treatment, and thereby improves her survival, will undoubtedly be elucidated in the next decade [85].

UR - http://www.scopus.com/inward/record.url?scp=84889976416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889976416&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-28266-2_44

DO - 10.1007/978-3-540-28266-2_44

M3 - Chapter

SN - 3540282653

SN - 9783540282655

SP - 945

EP - 975

BT - Breast Cancer and Molecular Medicine

PB - Springer Berlin Heidelberg

ER -